Noriko Sato, M.D., Ph.D.

Team Member of:
Dr. Noriko Sato leads the Laboratory of Cellular Therapeutics in the Molecular Imaging Branch at the National Cancer Institute. Dr. Sato received her M.D. and Ph.D. from Kyoto University, Japan. Her research interests are on 1) development and usage of imaging technologies to investigate behavior of cells in vivo, 2) understanding immune cell activation mechanisms, by combining imaging and non-imaging techniques, and 3) modification of tumor microenvironment to improve cancer therapies. She is currently working to bring a new ex vivo cell labeling method to the clinic for real time monitoring of cell-based therapies by PET imaging.
1) molecular imaging, 2) cell tracking, 3) T cell activation
Contact Info
Center for Cancer Research
National Cancer Institute
Building 10, Room B3B406
Bethesda, MD 20892-1002
Ph: 240-858-3079
Fax: 240-541-4527
saton@mail.nih.gov
Info. to come
Selected Recent Publications
-
Development of an IL-15-autocrine CD8 T-cell leukemia in IL-15-transgenic mice requires the cis expression of IL-15Ralpha.Blood. 117: 4032-4040, 2011. [ Journal Article ]
-
(89)Zr-Oxine Complex PET Cell Imaging in Monitoring Cell-based Therapies.Radiology. 275 (2): 490-500, 2015. [ Journal Article ]
-
Spatially selective depletion of tumor-associated regulatory T cells with near-infrared photoimmunotherapy..Sci Transl Med. 8(352): 352ra110, 2016. [ Journal Article ]
-
CD4 effector T cell differentiation is controlled by IL-15 that is expressed and presented in trans. .Cytokine. 99: 266-274, 2017. [ Journal Article ]
-
Bone marrow cell trafficking analyzed by 89Zr-oxine positron emission tomography in a murine transplantation model. .Clin Cancer Res. 23(11): 2759-2768, 2017. [ Journal Article ]
Dr. Noriko Sato leads the Laboratory of Cellular Therapeutics in the Molecular Imaging Branch at the National Cancer Institute. Dr. Sato received her M.D. and Ph.D. from Kyoto University, Japan. Her research interest is on the 1) development and use of imaging technologies to better understand immune cell activation, 2) modification of tumor microenvironment, and 3) exploring methods to improve cancer therapies. She is currently working to bring a new ex vivo cell labeling method to the clinic for real time monitoring of cell-based therapies by PET imaging.